Welcome to our dedicated page for OneMedNet SEC filings (Ticker: ONMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OneMedNet Corporation (NASDAQ: ONMD) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into OneMedNet’s corporate governance, capital structure, and public company obligations as it operates its iRWD™ Real-World Data platform and related services.
Among the key documents, investors can review OneMedNet’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe the company’s business, risk factors, and financial condition. Definitive proxy statements on Schedule 14A, such as the 2025 proxy, outline matters submitted to stockholders, including director elections, auditor ratification, and information about the annual meeting format and voting procedures. These materials also explain how stockholders of record and beneficial owners can participate in the company’s virtual annual meetings.
Current reports on Form 8-K are particularly important for tracking material events affecting ONMD. In 2025, for example, OneMedNet filed 8-Ks describing Nasdaq listing compliance updates related to the minimum bid price and market value of listed securities requirements, as well as board-related matters. Such filings help investors understand how the company is addressing exchange listing standards and corporate governance changes.
On Stock Titan, OneMedNet’s filings are updated as new documents are posted to the SEC’s EDGAR system. AI-powered summaries can assist readers by highlighting the main points of lengthy filings, such as changes in listing status, significant agreements, or governance proposals, while links to specific forms—10-K, 10-Q, 8-K, and DEF 14A—allow deeper review of the underlying disclosures.
OneMedNet Corp insider activity: a director and Chief Medical Officer reported multiple open-market purchases of OneMedNet common stock between December 8, 2023 and January 30, 2024, generally in small increments at prices ranging from about $0.48 to $1.36 per share, some reported as weighted average prices from multiple trades. On January 19, 2024, the insider also received 45,000 restricted stock units (RSUs) as director compensation under the 2022 Equity Incentive Plan for board service in fiscal year 2024; each RSU represents one share of common stock and vested on December 31, 2024. Following these transactions, the insider reported owning 2,507,351 shares directly and 1,311,970 shares indirectly through a trust for children with an independent trustee, for which beneficial ownership is disclaimed.
OneMedNet Corp director and Chief Executive Officer Aaron Green reported his initial beneficial ownership of the company’s securities. He directly holds 600,000 shares of common stock, described as restricted stock units granted on May 1, 2023 that vest over approximately three years, starting with one-third after the first anniversary and the rest in equal monthly installments.
Green also holds a senior secured convertible note issued on June 28, 2023 under a securities purchase agreement, convertible into common stock at the lower of
OneMedNet Corp director reports no beneficial ownership
A director of OneMedNet Corp (ONMD)11/07/2023. The filing identifies the reporting person as a director of the company and indicates that the form is filed by one reporting person only. In the remarks, it states that no securities are beneficially owned, meaning the director reports holding no OneMedNet common stock or derivative securities such as options or warrants as of the reported date.
OneMedNet Corp’s chief medical officer and director has filed a Form 3 reporting significant ownership of the company’s common stock. The insider directly holds 2,455,124 shares of common stock and has an additional 1,311,970 shares reported as indirectly owned through a trust for children, where an independent trustee holds investment control and beneficial ownership is disclaimed.
The filing also shows a senior secured convertible note issued under a June 28, 2023 securities purchase agreement, which is convertible into common stock at the lower of $10.00 per share or 92.5% of the lowest volume-weighted average trading price for the ten trading days before conversion, subject to a floor price, with maturity on November 7, 2024. In addition, the insider holds warrants for 31,916 shares of common stock at an exercise price of $10.00 per share, which are immediately exercisable and expire on November 7, 2028.
OneMedNet Corp director reports initial share ownership. A reporting person serving as a director of OneMedNet Corp disclosed beneficial ownership of 237,122 shares of common stock as of an event dated 08/14/2024. The filing is made by a single reporting person and does not list any derivative securities, focusing solely on currently beneficially owned common shares held directly.
OneMedNet Corp director reports no beneficial ownership on Form 3
OneMedNet Corp director filed an initial ownership report stating that no securities of the company are beneficially owned. The filing is made by a single reporting person in the capacity of director, and both the non-derivative and derivative security tables are effectively empty. A remark clarifies that no securities are beneficially owned, and a power of attorney authorizes the attorney-in-fact to sign the form on the reporting person’s behalf.
OneMedNet Corp reported an initial insider ownership filing on Form 3 for a director, with an event date of 02/25/2025. The filing indicates that no securities of OneMedNet Corp are beneficially owned by this reporting person. The form is filed by a single reporting person and is signed by an attorney-in-fact under a power of attorney.
OneMedNet Corp director reports no beneficial ownership on Form 3
A newly reported director of OneMedNet Corp (ONMD) has filed an initial statement of beneficial ownership on Form 3 for an event dated 10/01/2024. The filing identifies the reporting person’s relationship to the company as a Director and confirms that the form is filed by one reporting person only.
In the remarks section, the filing states that no securities are beneficially owned. A Power of Attorney (Exhibit 24) is noted, and the form is signed by an attorney-in-fact on 11/26/2025, documenting that, as of the reported event date, the director does not hold OneMedNet securities in either direct or indirect form.
OneMedNet Corporation filed Prospectus Supplement No. 2 to its Form S-1, registering a primary offering of up to 11,500,000 shares of common stock and a secondary offering of up to 28,152,560 shares for resale. The supplement updates the prospectus dated July 24, 2025 and attaches the company’s Q3 2025 Form 10-Q for the quarter ended September 30, 2025.
The company is an emerging growth company and notes that investing in its securities involves a high degree of risk, directing readers to the Risk Factors section of the prospectus. As context, shares outstanding were 51,005,205 as of November 7, 2025. The supplement must be read together with the base prospectus, and neither the SEC nor any state commission has approved or disapproved the securities.
OneMedNet Corporation reported Q3 2025 results with total revenue of $177K (vs. $142K a year ago), driven by web imaging revenue of $177K as subscription revenue was $0. Gross margin was -$222K, and operating loss was $2.24M. Net loss for the quarter was $741K (vs. $2.06M loss a year ago).
For the nine months, revenue was $468K (vs. $617K in 2024). Despite a $6.59M operating loss, the company recorded $339K net income, primarily from non-operating items, including gains on troubled debt restructurings. Cash was $149K with $600K in Bitcoin (5 units) as of September 30, 2025; total assets were $1.51M against current liabilities of $5.01M, and stockholders’ deficit was -$3.94M. Management states these conditions raise substantial doubt about the ability to continue as a going concern.
The company raised capital through June and August 2025 equity sales and related-party subscriptions, converted debt to equity (PIPE Notes and loan extensions), and repaid the Yorkville note after several conversions. Shares outstanding were 51,005,205 as of November 7, 2025.
FAQ
What is the current stock price of OneMedNet (ONMD)?
What is the market cap of OneMedNet (ONMD)?
